US5091404A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for restoring functionality in muscle tissue
Assignee: CONNECTICUT THE, University of
•
Filing: 1990-10-05
•
Granted: 1992-02-25
•
Expires: 2010-10-05
Abstract
Abstract The use of cyclocreatine to preserve and/or restore the physiological functionality of muscle tissue subject to ischemia.
Inventors
- 👤 Salwa A. Elgebaly
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 00:32
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
41 words
A method of preserving and/or restoring the physiological functionality of in vivo animal muscle tissue subject to ischemia comprising the step of administering cyclocreatine in an amount effective for restoring post-ischemic physiological function to said tissue to a substantially pre-ischemic level.
Claim 2
Independent Claim
41 words
A method of preserving and/or restoring the physiological functionality of in vivo animal muscle tissue subject to ischemia comprising the step of administering cyclocreatine in an amount effective for restoring post-ischemic physiological function to said tissue to a substantially pre-ischemic level.
Claim 3
Dependent Claim
18 words
The method of claim 1 wherein the cyclocreatine is dispersed in a fluid carrier prior to being administered.
Claim 4
Dependent Claim
19 words
The method of claim 1 wherein the cyclocreatine is dissolved in a liquid carrier having an essentially neutral pH.
Claim 5
Dependent Claim
23 words
The method of claim 1 wherein the cyclocreatine is dispersed in a carrier at a concentration substantially greater than one percent by weight.
Claim 6
Dependent Claim
16 words
The method of claim 4 wherein the concentration is about three percent by weight or more.
Claim 7
Dependent Claim
14 words
The method of claim 4 wherein the concentration is about five percent by weight.
Claim 8
Dependent Claim
19 words
The method of claim 4 wherein the concentration of cyclocreatine is sufficient to saturate the carrier at room temperature.
Claim 9
Dependent Claim
25 words
The method of claim 1 wherein the cyclocreatine is administered at a dosage level in excess of 2 grams per 70 kilograms of body weight.
Claim 10
Dependent Claim
24 words
The method of claim 1 wherein the cyclocreatine is administered at a dosage level greater than 6 grams per 70 kilograms of body weight.
Claim 11
Dependent Claim
13 words
The method of claim 1 wherein the cyclocreatine is administered prior to ischemia.
Claim 12
Dependent Claim
20 words
The method of claim 1 wherein the initiation of administration is at least about one half hour prior to ischemia.
Claim 13
Dependent Claim
11 words
The method of claim 1 wherein the administration continues during reperfusion.
Claim 14
Dependent Claim
23 words
The method of claim 1 wherein the muscle tissue is myocardial tissue and the administration is carried out prior to ischemia and reperfusion.
Claim 15
Dependent Claim
12 words
The method of claim 1 wherein the cyclocreatine is administered by injection.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-24 | 1995-08-26 | 1996-02-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-24 | 1999-08-26 | 2000-02-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-24 | 2003-08-26 | 2004-02-25 | $7700.00 | Window Closed / Lapsed |